Licensing status

Publication and contact information

Drug platforms

Optimizing antigen affinity in T cell tumor vaccines

Cell culture and mouse studies suggest strong T cell receptor (TCR) binding by antigens may not improve the efficacy of tumor vaccines. In cell culture and in mouse models for melanoma, fragments of the melanoma antigen silver homolog (SILV; PMEL17; GP100) with affinity below 10 mM for TCRs in vitro were no more potent at eliciting an immune response in vivo than fragments with about 10 mM affinity. Next steps include prescreening tumor antigens for optimal affinity in preparation for clinical trials.

SciBX 6(15); doi:10.1038/scibx.2013.376
Published online April 18, 2013

Patent and licensing status not applicable

Zhong, S. et al. Proc. Natl. Acad. Sci. USA; published online April 1, 2013;
Contact: Michelle Krogsgaard, New York University School of Medicine,
New York, N.Y.